Hagino, H.
Narita, R.
Yokoyama, Y.
Watanabe, M.
Tomomitsu, M.
Funding for this research was provided by:
Mochida Pharmaceutical Company
Article History
Received: 15 January 2019
Accepted: 28 May 2019
First Online: 26 June 2019
Compliance with ethical standards
:
: HH has received consulting fees for this study from Mochida Pharmaceutical and lecture fees or grants outside the submitted work from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. RN, YY, MW, and MT are employees of Mochida Pharmaceutical. All authors declared no other relationships/conditions/circumstances that present a potential conflict of interest, in accordance with the “Transparency guideline for the Relation between Corporate Activities and Medical Institutions” prepared by the Japan Pharmaceutical Manufacturers Association, corresponding in Japan to the Physicians Payment Sunshine Act.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.